Word: approachers
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
What's your particular take on this? And why did you take the approach that you took in your book...
...crossover effort can have limits. Entertainer-preacher Huckabee could simply end up being the best-liked candidate among people who will never vote for him. But he has already become the political embodiment of the megachurch approach: get people in the door with rock or cappuccino or stand-up?but get them in the door. "Religion and politics and show business are all about attracting people," Pelosi says. The big question is whether Huckabee can keep his lyrics from drowning out his music...
Even with its intoxicating supply of dopamine, the ventral tegmental couldn't do the love job on its own. Most people eventually do leave the poker game or the dinner table, after all. Something has to turn the exhilaration of a new partner into what can approach an obsession, and that something is the brain's nucleus accumbens, located slightly higher and farther forward than the ventral tegmental. Thrill signals that start in the lower brain are processed in the nucleus accumbens via not just dopamine but also serotonin and, importantly, oxytocin. If ever there was a substance designed...
...statement. In 1971, Folkman published what would become a landmark paper about the relationship between tumors and blood supply. Folkman persisted in the face of skepticism and eventually founded the field of angiogenesis, the study of the growth of new blood vessels. This led to a new approach to cancer treatment, in which the blood supply of tumors is targeted, at a time when surgery and chemotherapy drugs were overwhelmingly emphasized. Folkman’s contributions live on in the 1.2 million patients who have undergone treatment based on his research and in the more than 1,000 laboratories worldwide...
...road wasn't always easy, however. Folkman's first compound, which biotech companies rushed to test in people at the beginning of this decade, proved less effective in patients than in mice, giving skeptics yet another reason to doubt the approach. But that agent, dismissed by U.S. researchers, eventually won approval in 2005 for treating lung cancer in China, where it is extending the lives of non-small-cell lung cancer patients...